We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-1.26%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.91B
AUM Growth
-$2.56B
Cap. Flow
+$5.6B
Cap. Flow %
70.85%
Top 10 Hldgs %
34.65%
Holding
156
New
13
Increased
15
Reduced
59
Closed
23

Top Buys

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$7.7B
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$114M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$76.7M
4
FOLD
Amicus Therapeutics
FOLD
+$76.6M
5
SCPH
scPharmaceuticals
SCPH
+$48.1M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$172M
2
AET
Aetna Inc
AET
+$163M
3
BIIB icon
Biogen
BIIB
+$128M
4
MRK icon
Merck
MRK
+$108M
5
GILD icon
Gilead Sciences
GILD
+$107M

Sector Composition

Rank Sector Weight
1 Healthcare 91.1%
2 Financials 1.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
76
Xencor
XNCR
$1.47B
$22.4M 0.28%
1,022,100
+274,856
+37% +$5.96M
SVA
77
DELISTED
Sinovac Biotech, Ltd
SVA
$22.4M 0.28%
2,839,500
+172,000
+6% +$1.29M
GKOS icon
78
Glaukos
GKOS
$9.06B
$21.5M 0.27%
836,500
– –
MDT icon
79
Medtronic
MDT
$112B
$20.5M 0.26%
254,200
-624,800
-71% -$50M
UHS icon
80
Universal Health Services
UHS
$10.1B
$19.8M 0.25%
174,800
-494,200
-74% -$52.8M
IMGN
81
DELISTED
Immunogen Inc
IMGN
$18.2M 0.23%
2,834,126
-2,616,455
-48% -$16.1M
RNAC icon
82
Cartesian Therapeutics
RNAC
$224M
$18.1M 0.23%
61,427
– –
NVO
83
Novo Nordisk
NVO
$227B
$17.7M 0.22%
660,000
– –
STDY
84
DELISTED
SteadyMed Ltd
STDY
$15.7M 0.2%
4,246,196
– –
MNTA
85
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$15.7M 0.2%
1,125,900
-983,168
-47% -$13.3M
CELG
86
CALL
DELISTED
Celgene Corp
CELG
$15.7M 0.2%
+150,000
New +$16.9M
VRNA
87
DELISTED
Verona Pharma
VRNA
$14.8M 0.19%
1,250,396
+583,730
+88% +$7.58M
VNDA icon
88
Vanda Pharmaceuticals
VNDA
$306M
$14.7M 0.19%
967,859
– –
DBVT
89
DBV Technologies
DBVT
$805M
$14.2M 0.18%
57,850
+6,560
+13% +$1.9M
NTRA icon
90
Natera
NTRA
$35.9B
$14.2M 0.18%
1,576,190
– –
ZLAB icon
91
Zai Lab
ZLAB
$2.06B
$14M 0.18%
658,160
– –
NVTA
92
DELISTED
Invitae Corporation
NVTA
$13.8M 0.17%
1,518,197
– –
CTIC
93
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$13.4M 0.17%
5,000,000
– –
WMGIZ
94
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
$13.2M 0.17%
8,746,583
+33,495
+0.4% +$51.7K
CHRS icon
95
Coherus Oncology
CHRS
$224M
$12.9M 0.16%
1,471,500
+391,800
+36% +$4.19M
NUVA
96
DELISTED
NuVasive, Inc.
NUVA
$12.9M 0.16%
220,700
– –
ADAP
97
DELISTED
Adaptimmune Therapeutics
ADAP
$12.8M 0.16%
1,914,660
– –
SYBX
98
DELISTED
Synlogic
SYBX
$12.8M 0.16%
87,666
– –
SRRA
99
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$11.9M 0.15%
80,093
-12,500
-13% -$1.2M
HRTX icon
100
Heron Therapeutics
HRTX
$93.1M
$11.8M 0.15%
650,000
– –
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2017 Portfolio in Review

As of Q4 2017, OrbiMed held 156 positions worth $7.91B, down 24% from $10.5B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed deployed $5.6B of net new capital in Q4 2017, opening 13 new positions and adding to 15 existing holdings. Its largest new stake was Rhythm Pharmaceuticals: 2,901,295 shares worth $43.5M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 91% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Aetna Inc, an estimated $163M trimmed.

  • OrbiMed's largest Q4 2017 buy was Rhythm Pharmaceuticals: 2,901,295 shares worth $43.5M.
  • OrbiMed added most to Loxo Oncology, Inc in Q4 2017, an estimated $7.7B increase.
  • OrbiMed's biggest Q4 2017 reduction was Aetna Inc, cutting an estimated $163M.
  • OrbiMed fully exited Incyte in Q4 2017, selling an estimated $172M.
  • OrbiMed's ten largest holdings make up 35% of its $7.91B portfolio in Q4 2017.
  • OrbiMed opened 13 new positions and closed 23 in Q4 2017.
  • OrbiMed's portfolio value fell 24% quarter-over-quarter to $7.91B.

Based on OrbiMed's 13F filing for Q4 2017, filed 14 Feb 2018.